Home > Signaling Pathways>Metabolic Enzyme/Protease>Cytochrome P450>Pradefovir mesylate (Remofovir)
Pradefovir mesylate (Remofovir)

This product is for research use only, not for human use. We do not sell to patients.

Pradefovir mesylate (Remofovir)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
100mg$3850Check With Us
200mg$5775Check With Us
500mg$9745Check With Us
email: [email protected]        [email protected]

Cat #: V3958 CAS #: 625095-61-6 Purity ≥ 98%

Description: Pradefovir mesylate (formerly known as Remofovir mesylate, ICN-2001-3 mesylate, MB-06866 mesylate, MB-6866 mesylate, ICN-20013 mesylate) is an RTI (reverse transcriptase) inhibitor that has the potential for the treatment of chronic HBV infection.

References: Lin CC, et al. Metabolic activation of Pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31.

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular Weight (MW)519.90
Molecular FormulaC13H23ClN5O7PS
CAS No.625095-61-6
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: ≥ 120 mg/mLr
Water: N/Ar
Ethanol: N/A
SMILES CodeNC1=C2N=CN(CCOC[P@]3(OCC[C@@H](C4=CC=CC(Cl)=C4)O3)=O)C2=NC=N1.CS(=O)(O)=O
SynonymsRemofovir; ICN-2001-3; MB-06866; MB 06866; MB06866; MB6866; MB-6866; MB 6866; ICN-20013; ICN20013; ICN2001-3;
ProtocolIn VitroPradefovir is a cyclodiester prodrug of PMEA. It is one of the HepDirect prodrugs, which are designed to be efficiently and specifically activated through an oxidative reaction catalyzed by CYP3A4, which is located mainly in the liver. Pradefovir is converted to PMEA in human liver microsomes with a Km of 60 μM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 L/min.
In VivoDaily oral dosing of Pradefovir (300 mg/kg) to rats for 8 days does not affect body weight; liver weight; liver weight-body weight ratio; liver microsomal protein content; total CYP content; enzyme activities for CYP1A, CYP2B, and CYP3A; and apoprotein contents for CYP1A1, CYP2B1/2, CYP3A1/2, and CYP4A1/3, indicating that Pradefovir is not a CYP inducer in rats.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM1.9234 mL9.6172 mL19.2345 mL38.4689 mL
5mM0.3847 mL1.9234 mL3.8469 mL7.6938 mL
10mM0.1923 mL0.9617 mL1.9234 mL3.8469 mL
20mM0.0962 mL0.4809 mL0.9617 mL1.9234 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.